Arcturus Therapeutics Holdings (ARCT) Cash from Investing Activities (2018 - 2026)
Arcturus Therapeutics Holdings' (ARCT) quarterly Cash from Investing Activities came in at $34000.0 in Q1 2026, up 124.82% YoY from $15123.4 in Q1 2025, and down 61.36% on a QoQ basis from $88000.0 in Q4 2025.
Powered by 
Analysis
Arcturus Therapeutics Holdings (ARCT) Cash from Investing Activities (2018 - 2026) Analysis & Trends
Arcturus Therapeutics Holdings (ARCT) has 9 years of Cash from Investing Activities data on file, last reported at $34000.0 in Q1 2026.
- Quarterly Cash from Investing Activities rose 124.82% year-over-year to $34000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$59000.0 (up 89.17% YoY) and the FY2025 annual result came in at -$230000.0, up 64.51% from the prior year.
- Cash from Investing Activities fell to $34000.0 in Q1 2026, from $88000.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $378000.0 in Q2 2022 to a low of -$3.8 million in Q4 2022.
- A 5-year average of -$764733.3 and a median of -$328000.0 in 2024 frame the typical range for Cash from Investing Activities.
- The widest YoY moves for Cash from Investing Activities: up 193.56% in 2022, down 1688.98% in 2022.
- Tracing ARCT's Cash from Investing Activities over 5 years: stood at -$3.8 million in 2022, then jumped by 77.02% to -$875000.0 in 2023, then soared by 90.86% to -$80000.0 in 2024, then soared by 210.0% to $88000.0 in 2025, then tumbled by 61.36% to $34000.0 in 2026.
- The last three Cash from Investing Activities figures came in at $34000.0 (Q1 2026), $88000.0 (Q4 2025), and -$181000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Arcturus Therapeutics Holdings | 449.65 Mn | 258.17 Mn | - | 18,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 18,000.00 |
| Mar 31, 2026 | 34,000.00 |
| Dec 31, 2025 | 88,000.00 |
| Sep 30, 2025 | -181,000.00 |
| Mar 31, 2025 | -137,000.00 |
| Sep 30, 2024 | -80,000.00 |
| Jun 30, 2024 | -328,000.00 |
| Mar 31, 2024 | -240,000.00 |
| Dec 31, 2023 | -875,000.00 |
| Sep 30, 2023 | -981,000.00 |
| Jun 30, 2023 | -354,000.00 |
| Mar 31, 2023 | -691,000.00 |
| Dec 31, 2022 | -3.81 Mn |
| Sep 30, 2022 | -2.19 Mn |
| Jun 30, 2022 | 378,000.00 |
| Mar 31, 2022 | -2.11 Mn |
| Dec 31, 2021 | -1.12 Mn |
| Sep 30, 2021 | -1.77 Mn |
| Jun 30, 2021 | -404,000.00 |
| Mar 31, 2021 | -118,000.00 |